Swiss pharmaceutical company Roche has announced that a new antibiotic, zosurabalpin, is progressing to phase 3 testing.

Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Roche is planning to move a new antibiotic into late-stage clinical trials after studies showed it had potential to tackle a ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

FRANKFURT — Swiss drugmaker Roche (ROG.S), said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the ...

Australia’s second-largest private hospital operator, Healthscope, is in receivership with ten non-binding offers for ...

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

FRANKFURT, May 26 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious ...

Then $75 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial. Complete digital access to quality FT journalism with expert analysis from ...

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.